Tirzepatide

A clear starting point

Tirzepatide is a peptide agonist of two incretin receptors. FDA-approved Mounjaro and Zepbound products have defined indications rather than a general-purpose optimization approval.

Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.

No validated chemical structure is displayed in this edition.

How it works

GLP-1 / GIP signaling

Tirzepatide is a peptide agonist of two incretin receptors. FDA-approved Mounjaro and Zepbound products have defined indications rather than a general-purpose optimization approval.

Targets & processes

GLP-1 / GIP signaling

Systems & tissues

See the pathway description; category links describe research relevance, not demonstrated treatment effects.

What does the evidence show?

Glycemic and weight outcomes and other labeled disease-specific outcomes.

Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.

Safety is a separate question

Label warnings include thyroid C-cell tumors in rodents (human relevance unknown), GI effects, pancreatitis, gallbladder disease and dehydration-related kidney injury. Contraindicated with MTC/MEN2 or serious hypersensitivity. Oral contraceptive effectiveness can be affected; weight-loss use is inappropriate in pregnancy.

Contraindications & cautions

Not an exhaustive contraindication review. Label warnings include thyroid C-cell tumors in rodents (human relevance unknown), GI effects, pancreatitis, gallbladder disease and dehydration-related kidney injury. Contraindicated with MTC/MEN2 or serious hypersensitivity. Oral contraceptive effectiveness can be affected; weight-loss use is inappropriate in pregnancy.

Medication & supplement interactions

Interaction information is incomplete. Label warnings include thyroid C-cell tumors in rodents (human relevance unknown), GI effects, pancreatitis, gallbladder disease and dehydration-related kidney injury. Contraindicated with MTC/MEN2 or serious hypersensitivity. Oral contraceptive effectiveness can be affected; weight-loss use is inappropriate in pregnancy.

Regulatory status · United States

FDA-approved products · specific indications. Mounjaro and Zepbound have product-specific FDA approvals. Indications and eligible populations differ; approval does not extend to research preparations.

This is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.

Make the science interactive

A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.